XORTX Therapeutics Inc (XRTX) Stock Analysis

AI analysis of XORTX Therapeutics Inc (XRTX)

Sell

XORTX Therapeutics Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The stock is currently priced at $0.87, which is close to its 52-week low of $0.83, indicating weak market performance. Additionally, the RSI is at a low 24.41, suggesting the stock is oversold, but this does not guarantee a rebound. The company has reported a staggering year-to-date change of -69.47% and has a forward P/E ratio of 0.9621, indicating potential undervaluation but also reflecting ongoing financial struggles. The main risk is its negative net income, which reached -1,690,734 USD in Q2 2026, highlighting ongoing financial instability.

Valuation Metrics

The current forward P/E ratio for XORTX Therapeutics Inc (XRTX) is 0.96, compared to its 5-year average forward P/E of -0.97.

Forward P/E

Overvalued

5Y Average P/E

-0.97

Current P/E

0.96

Overvalued

0.17

Undervalued

-2.11

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

0.08

Current EV/EBITDA

0.00

Overvalued

0.32

Undervalued

-0.17

Forward P/S

Fair

5Y Average P/S

0.36

Current P/S

0.08

Overvalued

1.34

Undervalued

-0.61

Alphio AI Price Scenarios for XRTX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%XRTX

$0.91

Scenario price

B

Base

Base · 50%XRTX

$0.82

Scenario price

B

Bear

Bear · 25%XRTX

$0.78

Scenario price

XRTX FAQ — answered by Alphio AI

XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

XORTX Therapeutics Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The stock is currently priced at $0.87, which is close to its 52-week low of $0.83, indicating weak market performance. Additionally, the RSI is at a low 24.41, suggesting the stock is oversold, but this does not guarantee a rebound. The company has reported a staggering year-to-date change of -69.47% and has a forward P/E ratio of 0.9621, indicating potential undervaluation but also reflecting ongoing financial struggles. The main risk is its negative net income, which reached -1,690,734 USD in Q2 2026, highlighting ongoing financial instability.